Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Zogenix and Astellas co-promote migraine drug Sumavel; terminated

Executive Summary

Astellas Pharma US and neurology start-up Zogenix have agreed to exclusively co-promote in the US the latter's Sumavel DosePro (sumatriptan), which was approved last month for acute migraine with or without aura and cluster headaches.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Marketing (Licensing)

Related Companies